Skip to main content
Top
Published in: Clinical and Translational Oncology 4/2018

01-04-2018 | Clinical Guides in Oncology

Recommendations of the Spanish brachytherapy group (GEB) of Spanish Society of Radiation Oncology (SEOR) and the Spanish Society of Medical Physics (SEFM) for high-dose rate (HDR) non melanoma skin cancer brachytherapy

Authors: S. Rodríguez, M. Arenas, C. Gutierrez, J. Richart, J. Perez-Calatayud, F. Celada, M. Santos, A. Rovirosa

Published in: Clinical and Translational Oncology | Issue 4/2018

Login to get access

Abstract

Clinical indications of brachytherapy in non-melanoma skin cancers, description of applicators and dosimetry recommendations are described based on the literature review, clinical practice and experience of Spanish Group of Brachytherapy and Spanish Society of Medical Physics reported in the XIV Annual Consensus Meeting on Non Melanoma Skin Cancer Brachytherapy held in Benidorm, Alicante (Spain) on October 21st, 2016. All the recommendations for which consensus was achieved are highlighted in blue. Regular and small surfaces may be treated with Leipzig, Valencia, flap applicators or electronic brachytherapy (EBT). For irregular surfaces, customized molds or interstitial implants should be employed. The dose is prescribed at a maximum depth of 3–4 mm of the clinical target volume/planning target volume (CTV/PTV) in all cases except in flaps or molds in which 5 mm is appropriate. Interstitial brachytherapy should be used for CTV/PTV >5 mm. Different total doses and fraction sizes are used with very similar clinical and toxicity results. Hypofractionation is very useful twice or 3 times a week, being comfortable for patients and practical for Radiotherapy Departments. In interstitial brachytherapy 2 fractions twice a day are applied.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol. 2011;65:377–88.CrossRefPubMed Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol. 2011;65:377–88.CrossRefPubMed
2.
go back to reference Kowalik L, Lyczek J, Sawicki M, Kazalsky D. Individual applicator for brachytherapy for various sites of superficial malignant lesions. J Contemp Brachytherapy. 2013;5:45–9.CrossRefPubMedPubMedCentral Kowalik L, Lyczek J, Sawicki M, Kazalsky D. Individual applicator for brachytherapy for various sites of superficial malignant lesions. J Contemp Brachytherapy. 2013;5:45–9.CrossRefPubMedPubMedCentral
3.
go back to reference Skowronek J. Brachytherapy in the treatment of skin cancer: an overview. Postepy Dermatol Alergol. 2015;5:362–7.CrossRef Skowronek J. Brachytherapy in the treatment of skin cancer: an overview. Postepy Dermatol Alergol. 2015;5:362–7.CrossRef
4.
go back to reference Arenas M, Arguis M, Diez-Presa L, Henriquez I, Murcia-Mejía M, Gascón M, et al. Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment. Brachytherapy. 2015;14:859–65.CrossRefPubMed Arenas M, Arguis M, Diez-Presa L, Henriquez I, Murcia-Mejía M, Gascón M, et al. Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment. Brachytherapy. 2015;14:859–65.CrossRefPubMed
5.
go back to reference Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60:406–11.CrossRefPubMed Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60:406–11.CrossRefPubMed
6.
go back to reference Köhler-Brock A, Prager W, Pohlmann S, Kunzw S. The indications for and results of HDR after loading therapy in diseases of the skin and mucosa with standardized surface applicators (the Leipzig applicator). Strahlenther Onkol. 1999;175(4):170–4.CrossRefPubMed Köhler-Brock A, Prager W, Pohlmann S, Kunzw S. The indications for and results of HDR after loading therapy in diseases of the skin and mucosa with standardized surface applicators (the Leipzig applicator). Strahlenther Onkol. 1999;175(4):170–4.CrossRefPubMed
7.
go back to reference Rose JN, McLaughlin PY, Hanna TP, D’Souza D, Sur R, Falkson CB. Surface mold brachytherapy for nonmelanoma skin cancer: Canadian patterns of practice. Pract Radiat Oncol. 2014;4:398–403.CrossRefPubMed Rose JN, McLaughlin PY, Hanna TP, D’Souza D, Sur R, Falkson CB. Surface mold brachytherapy for nonmelanoma skin cancer: Canadian patterns of practice. Pract Radiat Oncol. 2014;4:398–403.CrossRefPubMed
8.
go back to reference Arenas M, Sabater S, Sintas A, Arguis M, Hernandez V, Arquez M, et al. Individualised 3D scanning and printing for non-melanoma skin cancer brachytherapy: a financial study for its integration into clinical workflow. J Contemp Brachytherapy. 2017;9(3):270–6.CrossRefPubMedPubMedCentral Arenas M, Sabater S, Sintas A, Arguis M, Hernandez V, Arquez M, et al. Individualised 3D scanning and printing for non-melanoma skin cancer brachytherapy: a financial study for its integration into clinical workflow. J Contemp Brachytherapy. 2017;9(3):270–6.CrossRefPubMedPubMedCentral
9.
10.
go back to reference Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C, Celada-Alvárez FJ, de Unamuno-Bustos B, LLavador-Ros M, et al. Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy. 2015;7(3):331–8. Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C, Celada-Alvárez FJ, de Unamuno-Bustos B, LLavador-Ros M, et al. Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy. 2015;7(3):331–8.
11.
go back to reference NCCN Clinical Practice Guidelines in Oncology. Squamous Cell Skin Cancer Version 1.2017 NCCN.org. NCCN Clinical Practice Guidelines in Oncology. Squamous Cell Skin Cancer Version 1.2017 NCCN.org.
12.
go back to reference NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer Version 1.2017 NCCN.org. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer Version 1.2017 NCCN.org.
13.
go back to reference TNM staging American Joint Committee on Cancer. 7th ed. In: Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM Classification of Malignant Tumors, 7th ed. Oxford: Wiley-Blackwell, 2009. 310 p. ISBN 978-1-4443-3241-4. TNM staging American Joint Committee on Cancer. 7th ed. In: Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM Classification of Malignant Tumors, 7th ed. Oxford: Wiley-Blackwell, 2009. 310 p. ISBN 978-1-4443-3241-4.
14.
go back to reference Pons-Llanas O, Ballester-Sánchez R, Celada-Álvarez FJ, Candela Juan C, García-Martinez T, Llavador-Ros M, et al. Clinical implementation of a new electronic brachytherapy system for skin brachytherapy. J Contemp Brachytherapy. 2014;6:417–23.CrossRefPubMedPubMedCentral Pons-Llanas O, Ballester-Sánchez R, Celada-Álvarez FJ, Candela Juan C, García-Martinez T, Llavador-Ros M, et al. Clinical implementation of a new electronic brachytherapy system for skin brachytherapy. J Contemp Brachytherapy. 2014;6:417–23.CrossRefPubMedPubMedCentral
15.
go back to reference Ouhib Z, Kasper M, Calatayud JP, Rodríguez S, et al. Aspects of dosimetry and clinical practice of skin brachytherapy: the American Brachytherapy Society working group report. Brachytherapy. 2015;14(6):840–58.CrossRefPubMed Ouhib Z, Kasper M, Calatayud JP, Rodríguez S, et al. Aspects of dosimetry and clinical practice of skin brachytherapy: the American Brachytherapy Society working group report. Brachytherapy. 2015;14(6):840–58.CrossRefPubMed
16.
go back to reference Fulkerson RK, Micka JA, DeWerd LA. Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part I. Electronic brachytherapy source. Med Phys. 2014;41(2):022103.CrossRefPubMedPubMedCentral Fulkerson RK, Micka JA, DeWerd LA. Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part I. Electronic brachytherapy source. Med Phys. 2014;41(2):022103.CrossRefPubMedPubMedCentral
17.
go back to reference Fulkerson RK, Micka JA, DeWerd LA. Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part II. High dose rate 192Ir sources. Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part II. Med Phys. 2014;41(2):022104.CrossRefPubMedPubMedCentral Fulkerson RK, Micka JA, DeWerd LA. Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part II. High dose rate 192Ir sources. Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part II. Med Phys. 2014;41(2):022104.CrossRefPubMedPubMedCentral
18.
go back to reference Perez-Calatayud J, Granero D, Ballester F, Puchades V, et al. A dosimetric study of Leipzig applicators. Int J Radiat Oncol Biol Phys. 2005;62(2):579–84.CrossRefPubMed Perez-Calatayud J, Granero D, Ballester F, Puchades V, et al. A dosimetric study of Leipzig applicators. Int J Radiat Oncol Biol Phys. 2005;62(2):579–84.CrossRefPubMed
19.
go back to reference Granero D, Pérez-Calatayud J, Gimeno J, Ballester F, et al. Design and evaluation of a HDR skin applicator with flattening filter. Med Phys. 2008;35(2):495–503.CrossRefPubMed Granero D, Pérez-Calatayud J, Gimeno J, Ballester F, et al. Design and evaluation of a HDR skin applicator with flattening filter. Med Phys. 2008;35(2):495–503.CrossRefPubMed
20.
go back to reference Granero D, Pérez-Calatayud J, Ballester F, Ouib Z. Radiation leakage study for the Valencia applicators. Med Phys. 2013;29:60–4.CrossRef Granero D, Pérez-Calatayud J, Ballester F, Ouib Z. Radiation leakage study for the Valencia applicators. Med Phys. 2013;29:60–4.CrossRef
21.
go back to reference Granero D, Candela-Juan C, Ballester F, Ouib Z, et al. Commissioning and quality assurance procedures for the HDR Valencia skin applicators. J Contemp Brachytherapy. 2016;8(5):441–7.CrossRefPubMedPubMedCentral Granero D, Candela-Juan C, Ballester F, Ouib Z, et al. Commissioning and quality assurance procedures for the HDR Valencia skin applicators. J Contemp Brachytherapy. 2016;8(5):441–7.CrossRefPubMedPubMedCentral
22.
go back to reference Ibañez-Rosello B, Bautista-Ballesteros JA, Candela-Juan C, Villaescusa JI, et al. Evaluation of the shielding in a treatment room with an electronic brachytherapy unit. J Radiol Prot. 2017;37(2):N5–12 (epub ahead of print).CrossRefPubMed Ibañez-Rosello B, Bautista-Ballesteros JA, Candela-Juan C, Villaescusa JI, et al. Evaluation of the shielding in a treatment room with an electronic brachytherapy unit. J Radiol Prot. 2017;37(2):N5–12 (epub ahead of print).CrossRefPubMed
23.
go back to reference Brenner DJ, Leu CS, Beatty JF, Shefer RE. Clinical relative biological effectiveness of low-energy X-rays emitted by miniature X-ray devices. Phys Med Biol. 1999;44(2):323–33.CrossRefPubMed Brenner DJ, Leu CS, Beatty JF, Shefer RE. Clinical relative biological effectiveness of low-energy X-rays emitted by miniature X-ray devices. Phys Med Biol. 1999;44(2):323–33.CrossRefPubMed
24.
go back to reference García-Martinez T, Chan J-P, Perez-Calatayud J, Ballester F. Dosimetric characteristics of a new unit for electronic skin brachytherapy. J Contemp Brachytherapy. 2014;6:45–53.CrossRefPubMedPubMedCentral García-Martinez T, Chan J-P, Perez-Calatayud J, Ballester F. Dosimetric characteristics of a new unit for electronic skin brachytherapy. J Contemp Brachytherapy. 2014;6:45–53.CrossRefPubMedPubMedCentral
25.
go back to reference Rivard MJ, Davis SD, De Werd LA, Rusch TW, Axelrod S. Calculated and measured brachytherapy dosimetry parameters in water for the Xoft Axxent X-ray source: an electronic brachytherapy source. Med Phys. 2006;33:4020–32.CrossRefPubMed Rivard MJ, Davis SD, De Werd LA, Rusch TW, Axelrod S. Calculated and measured brachytherapy dosimetry parameters in water for the Xoft Axxent X-ray source: an electronic brachytherapy source. Med Phys. 2006;33:4020–32.CrossRefPubMed
26.
go back to reference Lam SCP, Xu Y, Ingram G, et al. Dosimetric characteristics of INTRABEAM® flat and surface applicators. Transl Cancer Res. 2014;3:106–11. Lam SCP, Xu Y, Ingram G, et al. Dosimetric characteristics of INTRABEAM® flat and surface applicators. Transl Cancer Res. 2014;3:106–11.
27.
go back to reference Schneider F, Clausen S, Thölking T, Wenz F, Abo-Madyan Y. A novel approach for superficial intraoperative radiotherapy (IORT) using a 50 kV X-ray source: a technical and case report. J Appl Clin Med Phys. 2014;5:4502. Schneider F, Clausen S, Thölking T, Wenz F, Abo-Madyan Y. A novel approach for superficial intraoperative radiotherapy (IORT) using a 50 kV X-ray source: a technical and case report. J Appl Clin Med Phys. 2014;5:4502.
28.
go back to reference Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy. 2013;12:134–40.CrossRefPubMed Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy. 2013;12:134–40.CrossRefPubMed
29.
go back to reference Bhatnagar A, Patel R, Werschler WP, Ceilley RI, Strimling R. High-dose rate electronic brachytherapy: a nonsurgical treatment alternative for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2016;9(11):16–2.PubMedPubMedCentral Bhatnagar A, Patel R, Werschler WP, Ceilley RI, Strimling R. High-dose rate electronic brachytherapy: a nonsurgical treatment alternative for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2016;9(11):16–2.PubMedPubMedCentral
30.
go back to reference Jankarashvili N, Topeshashvili M. Treatment of skin cancer with intrabeam. 9th ZEISS INTRABEAM User Meeting. 2015. Jankarashvili N, Topeshashvili M. Treatment of skin cancer with intrabeam. 9th ZEISS INTRABEAM User Meeting. 2015.
31.
go back to reference Granero D, Vijande J, Ballester F, Rodríguez S, et al. Prescription depth in surface skin brachytherapy. Brachytherapy. 2017;16(3):S1.CrossRef Granero D, Vijande J, Ballester F, Rodríguez S, et al. Prescription depth in surface skin brachytherapy. Brachytherapy. 2017;16(3):S1.CrossRef
32.
go back to reference Granero D, Candela-Juan C, Vijande J, Ballester F, et al. Technical note: dosimetry of Leipzig and Valencia applicators without the plastic cap. Med Phys. 2016;43(5):2087.CrossRefPubMed Granero D, Candela-Juan C, Vijande J, Ballester F, et al. Technical note: dosimetry of Leipzig and Valencia applicators without the plastic cap. Med Phys. 2016;43(5):2087.CrossRefPubMed
33.
go back to reference Candela-Juan C, Niatsetski Y, Ouhib Z, Ballester F, et al. Commissioning and periodic tests of the Esteya® electronic brachytherapy system. J Contemp Brachytherapy. 2015;7(2):189–95.CrossRefPubMedPubMedCentral Candela-Juan C, Niatsetski Y, Ouhib Z, Ballester F, et al. Commissioning and periodic tests of the Esteya® electronic brachytherapy system. J Contemp Brachytherapy. 2015;7(2):189–95.CrossRefPubMedPubMedCentral
34.
go back to reference Rodriguez-Villalba S, Perez-calatayud MJ, Bautista JA, Carmona V, et al. Novel simple templates for reproducible positioning of skin applicators in brachytherapy. J Contemp Brachytherapy. 2016;8(4):1–5. Rodriguez-Villalba S, Perez-calatayud MJ, Bautista JA, Carmona V, et al. Novel simple templates for reproducible positioning of skin applicators in brachytherapy. J Contemp Brachytherapy. 2016;8(4):1–5.
35.
go back to reference Lliso F, Granero D, Perez-Calatayud J, Carmona V, Pujades MC, Ballester F. Dosimetric evaluation of internal shielding in a high dose rate skin applicator. J Contemp Brachytherapy. 2011;3(1):32–5.CrossRefPubMedPubMedCentral Lliso F, Granero D, Perez-Calatayud J, Carmona V, Pujades MC, Ballester F. Dosimetric evaluation of internal shielding in a high dose rate skin applicator. J Contemp Brachytherapy. 2011;3(1):32–5.CrossRefPubMedPubMedCentral
36.
go back to reference Granero D, Pérez-Calatayud J, Vijande J, Ballester F, Rivard MJ. Limitations of the TG-43 formalism for skin high-dose-rate brachytherapy dose calculations. Med Phys. 2014;41(2):021703.CrossRefPubMed Granero D, Pérez-Calatayud J, Vijande J, Ballester F, Rivard MJ. Limitations of the TG-43 formalism for skin high-dose-rate brachytherapy dose calculations. Med Phys. 2014;41(2):021703.CrossRefPubMed
37.
go back to reference Candela-Juan C, Granero D, Vijande J, Ballester F, Rivard MJ, et al. Dosimetric perturbations of a lead shield for surface and interstitial high-dose-rate brachytherapy. J Radiol Prot. 2014;34(2):297–311.CrossRefPubMed Candela-Juan C, Granero D, Vijande J, Ballester F, Rivard MJ, et al. Dosimetric perturbations of a lead shield for surface and interstitial high-dose-rate brachytherapy. J Radiol Prot. 2014;34(2):297–311.CrossRefPubMed
38.
go back to reference Safigholi H, Song WY, Meigooni AS. Optimum radiation source for radiation therapy of skin cancer. J Appl Clin Med Phys. 2015;16(5):5407.CrossRef Safigholi H, Song WY, Meigooni AS. Optimum radiation source for radiation therapy of skin cancer. J Appl Clin Med Phys. 2015;16(5):5407.CrossRef
39.
go back to reference Delishaj D, Rembielak A, Manfredi B, Ursino S, Pasqualetti F, Laliscia C, et al. Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature. J Contemp Brachytherapy. 2016;8(6):533–40.CrossRefPubMedPubMedCentral Delishaj D, Rembielak A, Manfredi B, Ursino S, Pasqualetti F, Laliscia C, et al. Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature. J Contemp Brachytherapy. 2016;8(6):533–40.CrossRefPubMedPubMedCentral
Metadata
Title
Recommendations of the Spanish brachytherapy group (GEB) of Spanish Society of Radiation Oncology (SEOR) and the Spanish Society of Medical Physics (SEFM) for high-dose rate (HDR) non melanoma skin cancer brachytherapy
Authors
S. Rodríguez
M. Arenas
C. Gutierrez
J. Richart
J. Perez-Calatayud
F. Celada
M. Santos
A. Rovirosa
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1733-z

Other articles of this Issue 4/2018

Clinical and Translational Oncology 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine